Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer

被引：9

作者：

Huang, Min ^{[1
]}

Fasching, Peter ^{[2
]}

Haiderali, Amin ^{[1
]}

Pan, Wilbur ^{[1
]}

Gray, Emma ^{[3
]}

Zhou, Zheng-Yi ^{[3
]}

Hu, Peter ^{[1
]}

Chaudhuri, Mitashri ^{[4
]}

De Tilleghem, Celine Le Bailly ^{[5
]}

Cappoen, Nicolas ^{[5
]}

O'Shaughnessy, Joyce ^{[6
]}

机构：

[1] Merck & Co Inc, Kenilworth, NJ 07033 USA

[2] Friedrich Alexander Univ Erlangen Nuremberg, Univ Hosp Erlangen, Comprehens Canc Ctr Erlangen EMN, Dept Gynecol & Obstet, Erlangen, Germany

[3] Anal Grp Inc, London, England

[4] Complete HEOR Solut CHEORS, N Wales, PA USA

[5] HTA Stat Europe, MSD, Brussels, Belgium

[6] Baylor Univ, Med Ctr, Texas Oncol & US Oncol, Dallas, TX USA

来源：

IMMUNOTHERAPY | 2022年 / 14卷 / 13期

关键词：

atezolizumab; cost-effectiveness; metastatic TNBC; PD-L1-positive; pembrolizumab; DOUBLE-BLIND; ATEZOLIZUMAB; PACLITAXEL; CRITERIA; PD-L1; TRIAL;

D O I：

10.2217/imt-2022-0082

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Objective: This study evaluated the cost-effectiveness of pembrolizumab/chemotherapy combinations for previously untreated metastatic triple-negative breast cancer patients in the USA with PD-L1 combined positive score >= 10. Methods: A partitioned-survival model was developed to project health outcomes and direct medical costs over a 20-year time horizon. Efficacy and safety data were from randomized clinical trials. Comparative effectiveness of indirect comparators was assessed using network meta-analyses. A series of sensitivity analyses were performed to test the robustness of the results. Results: Pembrolizumab/chemotherapy resulted in total quality-adjusted life-year (QALY) gains of 0.70 years and incremental cost-effectiveness ratio of US$182,732/QALY compared with chemotherapy alone. The incremental cost-effectiveness ratio for pembrolizumab/nab-paclitaxel versus atezolizumab/nab-paclitaxel was US$44,157/QALY. Sensitivity analyses showed the results were robust over plausible values of model inputs. Conclusion: Pembrolizumab/chemotherapy is cost effective compared with chemotherapy as well as atezolizumab/nab-paclitaxel as first-line treatment for PD-L1-positive metastatic triple-negative breast cancer from a US payer perspective.

引用

页码：1027 / 1041

页数：15

共 54 条

[1] Incidence Trends of Breast Cancer Molecular Subtypes by Age and Race/Ethnicity in the US From 2010 to 2016 [J].